Feb 7 | News
LONDON (AP) — GlaxoSmithKline PLC says it has returned to profit in the fourth quarter as restructuring costs and overheads declined.
|
Jan 16 | Articles
Vaccines continue to be one of the brighter spots for pharmaceutical companies in the current market, and revenues for vaccine products are expected to continue their double-digit growth in the future.
|
Jan 16 | News
Astex Pharmaceuticals, Inc. today announced that the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered into by SuperGen, Inc. and GlaxoSmithKline (GSK) in November 2009 is terminating and existing research work and assets generated under the CLIMB(TM) epigenetic collaboration will be transferred to GSK.
|
Jan 14 | News
GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina
|
Jan 9 | News
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* (fluticasone furoate “FF”/vilanterol “VI”) in patients with chronic obstructive pulmonary disease (COPD)...
|
Dec 23 2011 | News
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trial to evaluate the efficacy, safety and tolerability of BENLYSTA® (belimumab) administered subcutaneously (SC) once-weekly to...
|
Dec 23 2011 | News
GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world‟s poorest countries from pneumococcal disease. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in...
|
Dec 23 2011 | News
In February 2011 GSK announced its intention to divest non-core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate annual sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify...
|
Dec 22 2011 | News
Covis Pharma Sarl, a Switzerland-based specialty pharmaceutical company owned by affiliates of Cerberus Capital Management, L.P., today announced an agreement with GlaxoSmithKline to acquire full commercial rights for Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate), and Zantac Injection (ranitidine hydrochloride) in the United States and Puerto Rico.
|
Dec 16 2011 | News
Drugmakers Pfizer and GlaxoSmithKline announced Friday they have agreed to supply hundreds of millions of additional doses of pneumonia vaccine to an international partnership that provides immunization to children in developing countries.
|